TISIDB

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol Nucleus
Domain	-
Function	Arginine methyltransferase that can both catalyze the formation of omega-N monomethylarginine (MMA) and symmetrical dimethylarginine (sDMA), with a preference for the formation of MMA. Specifically mediates the symmetrical dimethylation of arginine residues in the small nuclear ribonucleoproteins Sm D1 (SNRPD1) and Sm D3 (SNRPD3); such methylation being required for the assembly and biogenesis of snRNP core particles. Specifically mediates the symmetric dimethylation of histone H4 'Arg-3' to form H4R3me2s. Plays a role in gene imprinting by being recruited by CTCFL at the H19 imprinted control region (ICR) and methylating histone H4 to form H4R3me2s, possibly leading to recruit DNA methyltransferases at these sites. May also play a role in embryonic stem cell (ESC) pluripotency. Also able to mediate the arginine methylation of histone H2A and myelin basic protein (MBP) in vitro; the relevance of such results is however unclear in vivo.

> Gene Ontology [ TOP ]
Biological Process	GO:0000375 RNA splicing, via transesterification reactions GO:0000377 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile GO:0000387 spliceosomal snRNP assembly GO:0000398 mRNA splicing, via spliceosome GO:0006304 DNA modification GO:0006305 DNA alkylation GO:0006306 DNA methylation GO:0006349 regulation of gene expression by genetic imprinting GO:0006397 mRNA processing GO:0006479 protein methylation GO:0008213 protein alkylation GO:0008380 RNA splicing GO:0016570 histone modification GO:0016571 histone methylation GO:0018195 peptidyl-arginine modification GO:0018216 peptidyl-arginine methylation GO:0019918 peptidyl-arginine methylation, to symmetrical-dimethyl arginine GO:0019919 peptidyl-arginine methylation, to asymmetrical-dimethyl arginine GO:0022613 ribonucleoprotein complex biogenesis GO:0022618 ribonucleoprotein complex assembly GO:0032259 methylation GO:0034969 histone arginine methylation GO:0035246 peptidyl-arginine N-methylation GO:0035247 peptidyl-arginine omega-N-methylation GO:0040029 regulation of gene expression, epigenetic GO:0043046 DNA methylation involved in gamete generation GO:0043393 regulation of protein binding GO:0043414 macromolecule methylation GO:0043985 histone H4-R3 methylation GO:0044728 DNA methylation or demethylation GO:0051098 regulation of binding GO:0071514 genetic imprinting GO:0071826 ribonucleoprotein complex subunit organization
Molecular Function	GO:0008168 methyltransferase activity GO:0008170 N-methyltransferase activity GO:0008276 protein methyltransferase activity GO:0008469 histone-arginine N-methyltransferase activity GO:0008757 S-adenosylmethionine-dependent methyltransferase activity GO:0016273 arginine N-methyltransferase activity GO:0016274 protein-arginine N-methyltransferase activity GO:0016277 [myelin basic protein]-arginine N-methyltransferase activity GO:0016741 transferase activity, transferring one-carbon groups GO:0035241 protein-arginine omega-N monomethyltransferase activity GO:0035242 protein-arginine omega-N asymmetric methyltransferase activity GO:0035243 protein-arginine omega-N symmetric methyltransferase activity GO:0042054 histone methyltransferase activity GO:0042393 histone binding GO:0043021 ribonucleoprotein complex binding GO:0044020 histone methyltransferase activity (H4-R3 specific)
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-3214858: RMTs methylate histone arginines

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PRMT7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PRMT7 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	STARS Score: 6.60; FDR: 0.000	Resistant to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX	STARS Score: 4.61; FDR: 0.008	Resistant to T cell-mediated killing
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PRMT7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.228	0.353
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.602	0.734
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.047	0.972
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.021	0.938
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.033	0.985
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.001	1
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.142	0.619
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.026	0.984
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.272	0.852
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.024	0.988
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.56	0.799
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.025	0.696

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PRMT7 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	4.1	-0.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	5.1	-1.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PRMT7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PRMT7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PRMT7. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PRMT7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PRMT7 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PRMT7 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PRMT7
Name	protein arginine methyltransferase 7
Aliases	FLJ10640; KIAA1933; [Myelin basic protein]-arginine N-methyltransferase PRMT7; histone-arginine N-methyltran ......
Chromosomal Location	16q22.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PRMT7 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PRMT7